The Scientific Basis for Chelation: Animal Studies and Lead Chelation

被引：17

作者：

Smith D. ^{[1
]}

Strupp B.J. ^{[2
]}

机构：

[1] Microbiology and Environmental Toxicology, University of California Santa Cruz, Santa Cruz, CA

[2] Division of Nutritional Sciences and Department of Psychology, Cornell University, Ithaca, NY

来源：

Journal of Medical Toxicology | 2013年 / 9卷 / 4期

基金：

美国国家卫生研究院;

关键词：

Autism; Brain lead; Lead poisoning; Neurobehavioral deficits; Succimer chelation treatment;

D O I：

10.1007/s13181-013-0339-2

中图分类号：

学科分类号：

摘要：

This presentation summarizes several of the rodent and non-human studies that we have conducted to help inform the efficacy and clinical utility of succimer (meso-2,3-dimercaptosuccincinic acid) chelation treatment. We address the following questions: (1) What is the extent of body lead, and in particular brain lead reduction with chelation, and do reductions in blood lead accurately reflect reductions in brain lead? (2) Can succimer treatment alleviate the neurobehavioral impacts of lead poisoning? And (3) does succimer treatment, in the absence of lead poisoning, produce neurobehavioral deficits? Results from our studies in juvenile primates show that succimer treatment is effective at accelerating the elimination of lead from the body, but chelation was only marginally better than the complete cessation of lead exposure alone. Studies in lead-exposed adult primates treated with a single 19-day course of succimer showed that chelation did not measurably reduce brain lead levels compared to vehicle-treated controls. A follow-up study in rodents that underwent one or two 21-day courses of succimer treatment showed that chelation significantly reduced brain lead levels, and that two courses of succimer were significantly more efficacious at reducing brain lead levels than one. In both the primate and rodent studies, reductions in blood lead levels were a relatively poor predictor of reductions in brain lead levels. Our studies in rodents demonstrated that it is possible for succimer chelation therapy to alleviate certain types of lead-induced behavioral/cognitive dysfunction, suggesting that if a succimer treatment protocol that produced a substantial reduction of brain lead levels could be identified for humans, a functional benefit might be derived. Finally, we also found that succimer treatment produced lasting adverse neurobehavioral effects when administered to non-lead-exposed rodents, highlighting the potential risks of administering succimer or other metal-chelating agents to children who do not have elevated tissue lead levels. It is of significant concern that this type of therapy has been advocated for treating autism. © 2013 American College of Medical Toxicology.

引用

页码：326 / 338

页数：12

共 22 条

[1]

Graziano J.H., Siris E.S., LoIacono N., Silverberg S.J., Turgeon L., 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication, Clin Pharmacol Ther, 37, pp. 431-438, (1985)

[2]

Graziano J.H., Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning, Med Toxicol, 1, pp. 155-162, (1986)

[3]

Graziano J.H., Lolacono N.J., Meyer P., Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations, J Pediatr, 113, 4, pp. 751-757, (1988)

[4]

Graziano J.H., Lolacono N.J., Moulton T., Mitchell M.E., Slavkovich V., Zarate C., Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication, J Pediatr, 120, 1, pp. 133-139, (1992)

[5]

Aposhian H.V., Maiorino R.M., Dart R.C., Perry D.F., Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects, Clin Pharmacol Ther, 45, pp. 520-526, (1989)

[6]

Aposhian H.V., Aposhian M.M., Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent, Annu Rev Pharmacol Toxicol, 30, pp. 279-306, (1990)

[7]

Rivera M., Zheng W., Aposhian H.V., Fernando Q., Determination and metabolism of dithiol chelating agents VIII. Metal complexes of meso-dimercaptosuccinic acid, Toxicol Appl Pharmacol, 100, pp. 96-106, (1989)

[8]

Maiorino R.M., Akins J.M., Blaha K., Carter D.E., Aposhian H.V., Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation, J Pharmacol Exp Ther, 254, 2, pp. 570-577, (1990)

[9]

Dart R.C., Hurlbut K.M., Maiorino R.M., Mayersohn M., Aposhian H.V., Hassen L.V., Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults, J Pediatr, 125, pp. 309-316, (1994)

[10]

Asiedu P., Moulton T., Blum C.B., Roldan E., Lolacono N.J., Graziano J.H., Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisoned children and normal adults, Environ Health Perspect, 103, 7-8, pp. 734-739, (1995)

← 1 2 3 →